Behçet's Disease and Eosinophil Cationic Protein

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Didem Arslan Tas, Cukurova University
ClinicalTrials.gov Identifier:
NCT01584778
First received: April 24, 2012
Last updated: April 25, 2012
Last verified: April 2012
  Purpose

Eosinophil cationic protein (ECP) is a matrix protein of eosinophils and has been reported to reflect eosinophil activity. Few studies have examined the role of eosinophils in the pathogenesis of Behçet's disease. The purpose of the present study is to investigate the serum ECP levels in BD and its relation to clinical activity.


Condition Intervention
Behçet's Disease
Other: eosinophil cationic protein

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: The Serum Eosinophil Cationic Protein Levels in Behçet's Disease and Its Relation to the Clinical Activity

Resource links provided by NLM:


Further study details as provided by Cukurova University:

Enrollment: 47
Study Start Date: January 2002
Study Completion Date: December 2002
Primary Completion Date: December 2002 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Behçet patients Other: eosinophil cationic protein
Serum eosinophil cationic protein levels
Other Name: ECP
Healthy controls Other: eosinophil cationic protein
Serum eosinophil cationic protein levels
Other Name: ECP
Allergic rhinitis (diseased) controls Other: eosinophil cationic protein
Serum eosinophil cationic protein levels
Other Name: ECP

Detailed Description:

Behçet's disease (BD) is a systemic vasculitis, characterized by recurrent oral aphthae, genital ulcers, uveitis, skin lesions, arthritis, gastrointestinal and neurologic manifestations. There has been a growing interest in research on the pathogenesis of the disease. Eosinophils has been implicated in the vascular injury associated with several vasculitis syndromes like Churg Strauss syndrome, temporal arteritis and Henoch-Schonlein purpura. In Behçet patients, serum IgE and eosinophils have been reported to be comparable with the controls but eosinophil activity has not been studied extensively. Eosinophil cationic protein (ECP) is a matrix protein of specific granules of eosinophils with considerable capacity to damage tissue and cells and has been reported to reflect eosinophil activity. Increased serum levels of ECP has been reported in patients with seasonal allergic rhinitis. Several immunomodulatory features of ECP has been reported, such as inhibition of the proliferative T-lymphocyte response to antigen, immunoglobulin production, proliferation of plasma cell lines and upregulation of ICAM-1. Procoagulant effects of ECP has also been reported. The present study was conducted in patients without usage of any confounding drugs that can effect serum ECP levels. The purpose of this study was to investigate the serum ECP levels in BD and its relation to the clinical activity.

Forty-seven consecutive patients with BD (22 active, 25 inactive) meeting International Study Group Criteria , 21 age and sex matched patients with allergic rhinitis and 21 apparently healthy controls were evaluated prospectively in Rheumatology-Immunology Outpatient Clinic. Clinical activity was defined according to the criteria proposed by "Behcet's Disease Research Committee of Japan" . Activity scoring was made according to the "Behçet's Disease Research Committee of Japan" which was proposed in 1994. Organ involvements of the patients were summarized.

Patients on corticosteroids or immunosuppressives were excluded. Colchicine was stopped 10 days prior to the blood collection in inactive patients. Blood was drawn from the active patients before starting treatment. Cases with any allergy history or parasitosis were excluded.

  Eligibility

Ages Eligible for Study:   16 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Consecutive Behçet patients of the outpatient clinic of the Rheumatology-Immunology Department of University Hospital

Criteria

Inclusion Criteria:

  • Consecutive Behçet patients who gave the written informed consent were included.

Exclusion Criteria:

  • Patients on corticosteroids or immunosuppressives were excluded.Cases with any allergy history or parasitosis were excluded.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01584778

Locations
Turkey
Cukurova University, Faculty of Medicine, Rheumatology-Immunology Department
Adana, Turkey, 01330
Sponsors and Collaborators
Cukurova University
Investigators
Study Chair: Hüseyin TE Ozer, Assoc. Prof. Cukurova University, Faculty of Medicine, Rheumatology-Immunology Department
Study Director: Eren Erken, Prof. Dr. Cukurova University, Faculty of Medicine, Rheumatology-Immunology Department
  More Information

No publications provided

Responsible Party: Didem Arslan Tas, Dr. Didem Arslan Tas, Cukurova University
ClinicalTrials.gov Identifier: NCT01584778     History of Changes
Other Study ID Numbers: TF.00.U.32.
Study First Received: April 24, 2012
Last Updated: April 25, 2012
Health Authority: Turkey: Ethics Committee

Keywords provided by Cukurova University:
Behçet's disease
Eosinophil cationic protein
Eosinophils

Additional relevant MeSH terms:
Behcet Syndrome
Mouth Diseases
Stomatognathic Diseases
Uveitis, Anterior
Panuveitis
Uveitis
Uveal Diseases
Eye Diseases
Vasculitis
Vascular Diseases
Cardiovascular Diseases
Skin Diseases, Vascular
Skin Diseases
Eosinophil Cationic Protein
Immunologic Factors
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on September 18, 2014